Decreasing Use of Luteinizing Hormone-Releasing Hormone Agonists in the United States is Independent of Reimbursement Changes: A Medicare and Veterans Health Administration Claims Analysis

Journal of Urology

Volumn 182, Issue 1, 2009, Pages 255-261

  Chang, Steven L ^a   Liao, Joseph C ^a,b   Shinghal, Rajesh ^a,c  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^c SANTA CLARA VALLEY MEDICAL CENTER   (United States)

Author keywords

antineoplastic agents; gonadotropin releasing hormone; Medicare; physician's practice patterns; prostatic neoplasms

Indexed keywords

ANDROGEN; GONADORELIN ANTAGONIST;

ARTICLE; BILLING AND CLAIMS; HEALTH CARE MANAGEMENT; HEALTH CARE SYSTEM; MEDICARE; ORCHIECTOMY; PRIORITY JOURNAL; REIMBURSEMENT; UNITED STATES; VETERAN;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; COST SAVINGS; DRUG UTILIZATION; HEALTH CARE COSTS; HEALTH CARE SURVEYS; HUMANS; INSURANCE CLAIM REPORTING; INSURANCE, HEALTH, REIMBURSEMENT; LUTEINIZING HORMONE; MALE; MEDICARE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PRESCRIPTIONS; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY; UNITED STATES; UNITED STATES DEPARTMENT OF VETERANS AFFAIRS;

EID: 67349173614     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2009.02.141     Document Type: Article

References (19)

1. Huggins C., Stevens Jr. R.E., and Hodges C.V. Studies on prostate cancer. II. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg 43 (1941) 209
2. Cooperberg M., Grossfeld G., Lubeck D., and Carroll P. National practice patterns and time trends in androgen ablation for localized prostate cancer. J Natl Cancer Inst 95 (2003) 981
3. Meng M., Grossfeld G., Sadetsky N., Mehta S.S., Lubeck D., and Carroll P.R. Contemporary patterns of androgen deprivation therapy use for newly diagnosed prostate cancer. Urology 60 (2002) 7
4. Center for Medicare and Medicaid Services. Part B Extract Summary System Data Files. http://www.cms.hhs.gov/NonIdentifiableDataFiles/03_PartBExtractSummarySystem.asp Accessed November 10, 2008
5. Centers for Medicare & Medicaid Services (CMS), HHS. Medicare program; changes to Medicare payment for drugs and physician fee schedule payments for calendar year 2004. Interim final rule with comment period. Fed Regist 69 (2004) 1083
6. Weight C.J., Klein E.A., and Jones J.S. Androgen deprivation falls as orchiectomy rates rise after changes in reimbursement in the U.S. Medicare population. Cancer 112 (2008) 2195
7. Litwin M.S., Shpall A.I., Dorey F., and Nguyen T.H. Quality-of-life outcomes in long-term survivors of advanced prostate cancer. Am J Clin Oncol 21 (1998) 327
8. Potosky A.L., Reeve B.B., Clegg L.X., Hoffman R., Stephenson R., Albertsen P., et al. Quality of life following localized prostate cancer treated initially with androgen deprivation therapy or no therapy. J Natl Cancer Inst 94 (2002) 430
9. Strum S.B., McDermed J.E., Scholz M.C., Johnson H., and Tisman G. Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade. Br J Urol 79 (1997) 933
10. Melton L.R., Alothman K., Khosla S., Achenbach S., Oberg A.L., and Zincke H. Fracture risk following bilateral orchiectomy. J Urol 169 (2003) 1747
11. Smith M.R., Finkelstein J.S., McGovern F.J., Zietman A.L., Fallon M.A., Schoenfeld D.A., et al. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab 87 (2002) 599
12. Smith J.C., Bennett S., Evans L.M., Kynaston H., Parmar M., Mason M.D., et al. The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab 86 (2001) 4261
13. Higano C.S. Side effects of androgen deprivation therapy: monitoring and minimizing toxicity. Urology 61 (2003) 32
14. D'Amico A.V., Denham J.W., Crook J., Chen M.H., Goldhaber S.Z., Lamb D.S., et al. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol 25 (2007) 2420
15. Bhandari M., Crook J., and Hussain M. Should intermittent androgen deprivation be used in routine clinical practice?. J Clin Oncol 23 (2005) 8212
16. Grossfeld G., Chaudhary U., Reese D., Carroll P.R., and Small E. Intermittent androgen deprivation: update of cycling characteristics in patients without clinically apparent metastatic prostate cancer. Urology 58 (2001) 240
17. Cooperberg M., Cowan J., Broering J., and Carroll P. High-risk prostate cancer in the United States, 1990-2007. World J Urol 26 (2008) 211
18. Polascik T., Mayes J.M., Sun L., Madden J., Moul J., and Mouraviev V. Pathologic stage T2a and T2b prostate cancer in the recent prostate-specific antigen era: implications for unilateral ablative therapy. Prostate 68 (2008) 1380
19. Collin S.M., Martin R.M., Metcalfe C., Gunnell D., Albertsen P.C., Neal D., et al. Prostate-cancer mortality in the USA and UK in 1975-2004: an ecological study. Lancet Oncol 9 (2008) 445